Tylosin tartrateCAS# 74610-55-2 |
- ABT-199
Catalog No.:BCC3614
CAS No.:1257044-40-8
- WEHI-539
Catalog No.:BCC2055
CAS No.:1431866-33-9
- HA14-1
Catalog No.:BCC3593
CAS No.:65673-63-4
- Obatoclax mesylate (GX15-070)
Catalog No.:BCC2234
CAS No.:803712-79-0
- ABT-263 (Navitoclax)
Catalog No.:BCC1272
CAS No.:923564-51-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 74610-55-2 | SDF | Download SDF |
| PubChem ID | 60196281 | Appearance | Powder |
| Formula | C50H83NO23 | M.Wt | 1066.19 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | H2O : ≥ 100 mg/mL (93.79 mM) DMSO : ≥ 100 mg/mL (93.79 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (2R,3R)-2,3-dihydroxybutanedioic acid;2-[(4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-[(2R,3R,4R,5S,6R)-5-[(2S,4R,5S,6S)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-5,9,13-trimethyl-2,10-dioxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde | ||
| SMILES | CCC1C(C=C(C=CC(=O)C(CC(C(C(C(CC(=O)O1)O)C)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CC=O)C)C)COC4C(C(C(C(O4)C)O)OC)OC.C(C(C(=O)O)O)(C(=O)O)O | ||
| Standard InChIKey | ICVKYYINQHWDLM-KBEWXLTPSA-N | ||
| Standard InChI | InChI=1S/C46H77NO17.C4H6O6/c1-13-33-30(22-58-45-42(57-12)41(56-11)37(52)26(5)60-45)18-23(2)14-15-31(49)24(3)19-29(16-17-48)39(25(4)32(50)20-34(51)62-33)64-44-38(53)36(47(9)10)40(27(6)61-44)63-35-21-46(8,55)43(54)28(7)59-35;5-1(3(7)8)2(6)4(9)10/h14-15,17-18,24-30,32-33,35-45,50,52-55H,13,16,19-22H2,1-12H3;1-2,5-6H,(H,7,8)(H,9,10)/b15-14+,23-18+;/t24-,25+,26-,27-,28+,29+,30-,32-,33-,35+,36-,37-,38-,39-,40-,41-,42-,43+,44+,45-,46-;1-,2-/m11/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Tylosin Tartrate is an antibiotic with a large macrocyclic lactone ring.
Target: Antibacterial
Tylosin is a bacteriostat food additive used in veterinary medicine. It has a broad spectrum of activity against gram-positive organisms and a limited range of gram-negative organisms. There is no significant evidence that tylosin resistant staphylococci of animal origin have endangered human health. Tylosin is not effective against the gram-negative intestinal flora, which thus does not lead to selection of R-factors by conjugation. From the human medical stand point, there is no reason that precludes the use of tylosin as a fee additive in animal feeds [1]. Minimum inhibitory concentrations for tylosin tartrate and other commonly used antibiotics were determined for 103 isolates. Most (82.61%) of the isolates not exposed to antibiotics in the 3 months before submission were sensitive to tylosin tartrate. These findings suggest that tylosin tartrate warrants further study as a first-line option for the treatment of dogs initially presenting with pyoderma [2]. References: | |||||
Tylosin tartrate Dilution Calculator
Tylosin tartrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 0.9379 mL | 4.6896 mL | 9.3792 mL | 18.7584 mL | 23.448 mL |
| 5 mM | 0.1876 mL | 0.9379 mL | 1.8758 mL | 3.7517 mL | 4.6896 mL |
| 10 mM | 0.0938 mL | 0.469 mL | 0.9379 mL | 1.8758 mL | 2.3448 mL |
| 50 mM | 0.0188 mL | 0.0938 mL | 0.1876 mL | 0.3752 mL | 0.469 mL |
| 100 mM | 0.0094 mL | 0.0469 mL | 0.0938 mL | 0.1876 mL | 0.2345 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Tylosin tartrate is a macrolide antibiotic approved for the control of mycoplasmosis in poultry.
- Tetrahydrocoptisine
Catalog No.:BCN2558
CAS No.:7461-02-1
- Rubiadin 1-methyl ether
Catalog No.:BCN4298
CAS No.:7460-43-7
- D-64131
Catalog No.:BCC1510
CAS No.:74588-78-6
- Isomedicarpin
Catalog No.:BCN4297
CAS No.:74560-05-7
- Cristacarpin
Catalog No.:BCN3935
CAS No.:74515-47-2
- UBP 302
Catalog No.:BCC7256
CAS No.:745055-91-8
- UBP 296
Catalog No.:BCC7255
CAS No.:745055-86-1
- Ivachtin
Catalog No.:BCC2357
CAS No.:745046-84-8
- MMAF
Catalog No.:BCC5144
CAS No.:745017-94-1
- Alprostadil
Catalog No.:BCC4963
CAS No.:745-65-3
- Casegravol
Catalog No.:BCN4591
CAS No.:74474-76-3
- Potassium Chloride
Catalog No.:BCC7581
CAS No.:7447-40-7
- ent-3Beta-Angeloyloxykaur-16-en-19-oic acid
Catalog No.:BCN1365
CAS No.:74635-61-3
- 11-Hydroxydrim-7-en-6-one
Catalog No.:BCN7770
CAS No.:74635-87-3
- Liquiritin Apioside
Catalog No.:BCC8334
CAS No.:74639-14-8
- 1,3,9-Trimethyluric acid
Catalog No.:BCN7393
CAS No.:7464-93-9
- Nuclear yellow
Catalog No.:BCC1810
CAS No.:74681-68-8
- 3-Methoxy-4,5-methylenedioxycinnamaldehyde
Catalog No.:BCN1364
CAS No.:74683-19-5
- 4-hydroxy-1-methoxycarbonyl-beta-carboline
Catalog No.:BCN7909
CAS No.:74690-72-5
- 1-Methoxycarbonyl-beta-carboline-N-oxide
Catalog No.:BCN8205
CAS No.:74690-74-7
- Vibsanin C
Catalog No.:BCN4590
CAS No.:74690-89-4
- Hydroxychloroquine Sulfate
Catalog No.:BCC5560
CAS No.:747-36-4
- 5-Hydroxyxanthotoxin
Catalog No.:BCC8107
CAS No.:7471-73-0
- Zaltoprofen
Catalog No.:BCC4442
CAS No.:74711-43-6
Efficacy of tylosin tartrate on canine Staphylococcus intermedius isolates in vitro.[Pubmed:20960412]
Vet Ther. 2010 Fall;11(3):E1-7.
In the past 5 years, the incidence of canine skin infections caused by resistant strains of Staphylococcus (pseud)intermedius has increased. Many older antibiotics are used to treat these infections because the sensitivity can be demonstrated in vitro. Additionally, many of these older drugs are efficacious and unlikely to induce multidrug resistance. More than a decade ago, the antibiotic Tylosin tartrate was reported to be efficacious in vitro and in vivo against Staphylococcus intermedius. The purpose of this study was to determine whether S. (pseud)intermedius isolated from untreated pyoderma cases at veterinary referral centers across the United States are sensitive in vitro to this antibiotic. Minimum inhibitory concentrations for Tylosin tartrate and other commonly used antibiotics were determined for 103 isolates. Most (82.61%) of the isolates not exposed to antibiotics in the 3 months before submission were sensitive to Tylosin tartrate. These findings suggest that Tylosin tartrate warrants further study as a first-line option for the treatment of dogs initially presenting with pyoderma.
Effect of tylosin tartrate (Tylan Soluble) on cellular immune responses in chickens.[Pubmed:9733118]
Poult Sci. 1998 Sep;77(9):1306-11.
Although many antimicrobial agents have been reported to cause immunosuppression in animals, macrolide antibiotics enhance immune function. Tylosin is a macrolide antibiotic approved for the control of mycoplasmosis in poultry. The purpose of this investigation was to determine the effect of tylosin on cellular immune functions in chickens. There was no significant difference in adherent splenocyte chemotaxis between tylosin-treated and untreated (control) chickens. Tylosin increased splenocyte proliferation and splenocyte conditioned medium (CM) proliferative activity above control levels. Removal of adherent splenocytes before preparation of CM caused a reduction in CM proliferative activity. Tylosin also increased antitumor activity of splenocytes. These data are the first to suggest that the macrolide antibiotic, Tylosin tartrate, has a modulatory effect in chickens on the immune parameters studied.
Inhibition of microbial metabolism in anaerobic lagoons by selected sulfonamides, tetracyclines, lincomycin, and tylosin tartrate.[Pubmed:15839550]
Environ Toxicol Chem. 2005 Apr;24(4):782-8.
Antibiotics are used to maintain healthy livestock and to promote weight gain in concentrated animal feed operations. Antibiotics rarely are metabolized completely by livestock and, thus, are often present in livestock waste and in waste-treatment lagoons. The introduction of antibiotics into anaerobic lagoons commonly used for swine waste treatment has the potential for negative impacts on lagoon performance, which relies on a consortium of microbes ranging from fermentative microorganisms to methanogens. To address this concern, the effects of eight common veterinary antibiotics on anaerobic activity were studied. Anaerobic microcosms, prepared from freshly collected lagoon slurries, were amended with individual antibiotics at 10 mg/L for the initial screening study and at 1, 5, and 25 mg/L for the dose-response study. Monitored metabolic indicators included hydrogen, methane, and volatile fatty acid concentrations as well as chemical oxygen demand. The selected antibiotics significantly inhibited methane production relative to unamended controls, thus indicating that antibiotics at concentrations commonly found in swine lagoons can negatively impact anaerobic metabolism. Additionally, historical antibiotic usage seems to be a potential factor in affecting methane production. Specifically, less inhibition of methane production was noted in samples taken from the lagoon with a history of multiple-antibiotic use.
Comparative pharmacokinetics and bioavailability of tylosin tartrate and tylosin phosphate after a single oral and i.v. administration in chickens.[Pubmed:24325541]
J Vet Pharmacol Ther. 2014 Jun;37(3):312-5.
The pharmacokinetics and oral bioavailability of Tylosin tartrate and tylosin phosphate were carried out in broiler chickens according to a principle of single dose, random, parallel design. The two formulations of tylosin were given orally and intravenously at a dose level of 10 mg/kg b.w to chicken after an overnight fasting (n = 10 chickens/group). Serial blood samples were collected at different time points up to 24 h postdrug administration. A high performance liquid chromatography method was used for the determination of tylosin concentrations in chicken plasma. The tylosin plasma concentration's time plot of each chicken was analyzed by the 3P97 software. The pharmacokinetics of tylosin was best described by a one-compartmental open model 1st absorption after oral administration. After intravenous administration the pharmacokinetics of tylosin was best described by a two-compartmental open model, and there were no significant differences between Tylosin tartrate and tylosin phosphate. After oral administration, there were significant differences in the Cmax (0.18 +/- 0.01, 0.44 +/- 0.09) and AUC (0.82 +/- 0.05, 1.57 +/- 0.25)between tylosin phosphate and Tylosin tartrate. The calculated oral bioavailability (F) of Tylosin tartrate and tylosin phosphate were 25.78% and 13.73%, respectively. Above all, we can reasonably conclude that, the absorption of Tylosin tartrate is better than tylosin phosphate after oral administration.
